Hybridization of antisense reagents to RNA

Current Opinion in Molecular Therapeutics

Volumn 2, Issue 3, 2000, Pages 264-271

  Sohail, Muhammad ^a   Southern, Edwin M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Antisense oligonucleotides; Intermolecular hybridization; mRNA 1 4; RNase H

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; HETERODUPLEX;

BINDING SITE; DRUG DESIGN; DRUG STRUCTURE; GENE MAPPING; PROTEIN FOLDING; REVIEW; RNA BINDING; RNA HYBRIDIZATION;

ANIMALS; BINDING SITES; HUMANS; NUCLEIC ACID CONFORMATION; NUCLEIC ACID HETERODUPLEXES; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDES, ANTISENSE; RNA; RNA, MESSENGER;

EID: 0033947287     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Lima WF, Monia BP, Ecker DJ, Freier SM: Implication of RNA structure on antisense oligonucleotide hybridization kinetics. Biochemistry (1992) 31:12055-12061.
2. Southern EM, Case-Green SC, Elder JK, Johnson M, Mir KU, Wang L, Williams JC: Arrays of complementary oligonucleotides for analyzing the hybridization behavior of nucleic acids. Nucleic Acids Res (1994) 22:1368-1373.
3. Wagner RW, Matteucci MD, Grant D, Huang T, Froehler BC: Potent and selective inhibition of gene expression by an antisense heptanucleotide. Nature Biotechnol (1996) 14:840-844.
4. Birikh KR, Berlin YA, Soreq H, Eckstein F: Probing accessible sites for ribozymes on human acetylcholinesterase RNA. RNA (1997) 3:429-437.
5. Bruice TW, Lima WF: Control of complexity constraints on combinatorial screening for preferred oligonucleotide hybridization sites on structured RNA. Biochemistry (1997) 36:5004-5019.
6. Milner N, Mir KU, Southern EM: Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nature Biotechnol (1997) 15:537-541.
7. Ho SP, Bao Y, Lesher T, Malhotra R, Ma LY, Fluharty SJ, Sakai RR: Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nature Biotechnol (1998) 16:59-63.
8. Patzel V, Sczakiel G: Theoretical design of antisense RNA structures substantially improves annealing kinetics and efficacy in human cells. Nature Biotechnol (1998) 16:64-68.
9. Mir KU, Southern EM: Determining the influence of structure on hybridization using oligonucleotide arrays. Nature Biotechnol (1999) 17:788-792.
10. Sohail M, Akhtar S, Southern EM: The folding of large RNAs studied by hybridization to arrays of complementary oligonucleotides. RNA (1999) 5:646-655.
11. Tu GC, Cao QN, Zhou F, Israel Y: Tetranucleotide GGGA motif in primary RNA transcripts. Novel target site for antisense design. J Biol Chem (1998) 273:25125-25131.
12. Ramos A, Gubser CC, Varani G: Recent solution structures of RNA and its complexes with drugs, peptides and proteins. Curr Opin Struct Biol (1997) 7:317-323.
13. Bashirullah A, Cooperstock RL, Lipshitz HD: RNA localization in development. Annu Rev Biochem (1998) 67:335-394.
14. Tsuchihashi Z, Khosla M, Herschlag D: Protein enhancement of hammerhead ribozyme catalysis. Science (1993) 262:99-102.
15. Bertrand EL, Rossi JJ: Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein A1. EMBO J (1994) 13:2904-2912.
16. Coetzee T, Herschlag D, Belfort M: Escherichia coli proteins, including ribosomal protein S12, facilitate in vitro splicing of phage T4 introns by acting as RNA chaperones. Genes Dev (1994) 8:1575-1588.
17. Herschlag D, Khosla M, Tsuchihashi Z, Karpel RL: An RNA chaperone activity of non-specific RNA-binding proteins in hammerhead ribozyme catalysis. EMBO J (1994) 13:2913-2924.
18. Weeks KM: Protein-facilitated RNA folding. Curr Opin Struct Biol (1997) 7:336-342.
19. Revers F, Cario M, Cao TL, Cazenave C: Detection of proteins binding to short RNA/DNA hybrids or short antisense oligonucleotides in Xenopus laevis oocytes and human macrophage cell extracts by photoaffinity radiolabeling. Antisense Nucleic Acid Drug Dev (1999) 9:317-331.
20. Kozak M: Features in the 5′ non-coding sequences of rabbit α and β-globin mRNAs that affect translational efficiency. J Mol Biol (1994) 235:95-110.
21. Kozak M: Structural features in eukaryotic mRNAs that modulate the initiation of translation. J Biol Chem (1991) 266:19867-19870.
22. Decker CJ, Parker R: Diversity of cytoplasmic functions for 3′ untranslated region of eukaryotic transcripts. Curr Opin Cell Biol (1995) 7:386-392.
23. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D: Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med (1996) 2:668-675.
24. Mologni L, Nielsen PE, Gambacorti-Passerini C: In vitro transcriptional and translational block of the bcl-2 gene operated by peptide nucleic acid. Biochem Biophys Res Commun (1999) 264:537-543.
25. O'Dwyer PJ, Stevenson JP, Gallagher M, Cassella A, Vasilevskaya I, Monia BP, Holmlund J, Dorr FA, Yao KS: c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS-5132 (CGP-69846A). Clin Cancer Res (1999) 5:3977-3982.
26. Nussinov R, Jacobson AB: Fast algorithm for predicting the secondary structure of single stranded RNA. Proc Natl Acad Sci USA (1980) 77:6903-6913.
27. Dumas JP, Ninio J: Efficient algorithms for folding and comparing nucleic acid sequences. Nucleic Acids Res (1982) 10:197-206.
28. Zuker M: On finding all suboptimal foldings of an RNA molecule. Science (1989) 244:48-52.
29. Mathews DH, Sabina J, Zuker M, Tumer DH: Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J Mol Biol (1999) 288:911-940.
30. Tinoco I, Borer PN, Dengler B, Levine MD, Uhlenbeck OC, Crothers DM, Bralla J: Improved estimation of secondary structure in ribonucleic acids. Nature New Biol (1973) 246:40-41.
31. Lesnik EA, Freier SM: Relative thermodynamic stability of DNA, RNA and DNA:RNA hybrid duplexes: Relationship with base composition and structure. Biochemistry (1995) 34:10807-10815.
32. Sugimoto N, Nakano S, Katoh M, Matsumura A, Nakamuta H, Ohmichi T, Yoneyama M, Sasaki M: Thermodynamic parameters to predict stability of RNA/DNA hybrid duplexes. Biochemistry (1995) 34:11211-11216.
33. Laptev AV, Lu Z, Colige A, Prockop DJ: Specific inhibition of expression of a human collagen gene (COL1A1) with modified antisense oligonucleotides. The most effective target sites are clustered in double stranded regions of the predicted secondary structure for the mRNA. Biochemistry (1994) 33:11033-11039.
34. Thierry AR, Rahman A, Dritschilo A: Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. Biochem Biophys Res Commun (1993) 190:952-960.
35. Michel F, Westhof E: Modelling of the three-dimensional architecture of group I catalytic introns based on comparative sequence analysis. J Mol Biol (1990) 216:585-610.
36. Gaspin C, Westhof E: An interactive framework for RNA secondary structure prediction with a dynamical treatment of constraints. J Mol Biol (1995) 254:163-174.
37. Mathews DH, Burkard ME, Freier SM, Wyatt JR, Tumer DH: Predicting oligonucleotide affinity to nucleic acid targets. RNA (1999) 5:1458-1469.
38. Ho SP, Britton DHO, Stone BA, Behrens DL, Leffet LM, Hobbs FW, Miller JA, Trainor GL: Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucleic Acids Res (1996) 24:1901-1907.
39. Patzel V, Steidl U, Kronenwett R, Haas R, Sczakiel G: A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability. Nucleic Acids Res (1999) 27:4328-4334.
40. Puri N, Chattopadhyaya J: How kinetically accessible is an RNA target for hybridization with an antisense oligo? A lesson from an RNA target that is as small as 20 mer. Tetrahedron (1999) 55:1505-1516.
41. Phe. FEBS Lett (1999) 444:217-221.
42. Yu Q, Pecchia DB, Kingsley SL, Heckman JE, Burke JM: Cleavage of highly structured viral RNA molecules by combinatorial libraries of hairpin ribozymes. The most effective ribozymes are not predicted by substrate selection rules. J Biol Chem (1998) 273:23524-23533.
43. Campbell TB, Cech TR: Identification of ribozymes within a ribozyme library that efficiently cleave a long substrate RNA. RNA (1995) 1:598-609.
44. Lieber A, Strauss M: Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library. Mol Cell Biol (1995) 15:540-551.
45. Lima WF, Brown-Driver V, Fox M, Hanecak R, Bruice TW: Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. J Biol Chem (1997) 272:626-638.
46. Matveeva O, Felden B, Audlin S, Gesteland RF, Atkins JF: A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: Correlation with an intracellular pattern and known RNA structures. Nucleic Acids Res (1997) 25:5010-5016.
47. Caims MJ, Hopkins TM, Witherington C, Wang L, Sun L-Q: Target site selection for an RNA-cleaving catalytic DNA. Nature Biotechnol (1999) 17:480-486.
48. Branch AD: Antisense drug discovery: Can cell-free screens speed the process? Antisense Nucleic Acid Drug Dev (1998) 8:249-254.
49. Sohail M, Southern EM: Selecting optimal antisense oligonucleotides. Adv Drug Deliv Rev (2000) in press.
50. Sohail M, Southern EM: Antisense arrays. Mol Cell Biol Res Comm (2000) 3:67-72.
51. Sohail M, Southern EM: Using oligonucleotide scanning arrays to find effective antisense reagents. In: Methods in Molecular Biology: Oligonucleotide Array Methods and Protocols. Rampai JB (Ed), Humana Press, NJ, USA (2000) in press.
52. Verma S, Eckstein F: Modified oligonucleotides: Synthesis and strategy for users. Annu Rev Biochem (1998) 67:99-134.
53. Iyer RP, Roland A, Zhou W, Ghosh K: Modified oligonucleotides - synthesis, properties and applications. Curr Opin Mol Ther (1999) 1:344-358.
54. Dagle JM, Andracki ME, DeVine RJ, Walder JA: Physical properties of oligonucleotides containing phosphoramidite-modified internucleoside linkages. Nucleic Acids Res (1991) 19:1805-1810.
55. Young S, Wagner RW: Hybridization and dissociation rates of phosphodiester or modified oligodeoxynucleotides with RNA at near-physiological conditions. Nucleic Acids Res (1991) 19:2463-2470.
56. Marshall WS, Caruthers MH: Phosphorodithioate DNA as a potential therapeutic drug. Science (1993) 259:1564-1570.
57. Brown DA, Kang SH, Gryaznov SM, DeDionisio L, Heidenreich O, Sullivan S, Xu X, Nerenberg MI: Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein-binding. J Biol Chem (1994) 269:26801-26805.
58. McKay RA, Cummins LL, Graham MJ, Lesnik EA, Owens SR, Winniman M, Dean NM: Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-α by the incorporation of 2′-O-propyl modifications. Nucleic Acids Res (1996) 24:411-417.
59. Monia BP, Johnston JF, Sasmor H, Cummins LL: Nuclease resistance and antisense activity of modified oigonucleotides targeted to Ha-ras. J Biol Chem (1996) 271:14533-14540.
60. Agrawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, Roskey A, Channavajjala L, Saxinger C, Zhang R: Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies. Proc Natl Acad Sci USA (1997) 94:2620-2625.
61. Dean NM, Griffey RH: Identification and characterization of second generation antisense oligonucleotides. Antisense Nucleic Acid Drug Dev (1997) 7:229-233.
62. Agrawal S, Zhao Q: Antisense therapeutics. Curr Opin Chem Biol (1998) 2:519-528.
63. Agrawal S: Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim Biophys Acta (1999) 1489:53-67.
64. Chen D, Van Z, Cole DL, Srivatsa GS: Analysis of internal (n-1)mer deletion sequences in synthetic oligodeoxyribonucleotides by hybridization to an immobilized probe array. Nucleic Acids Res (1999) 27:389-395.
65. Hertel KJ, Herschlag D, Uhlenbeck OC: Specificity of hammerhead ribozyme cleavage. EMBO J (1996) 15:3751-3757.
66. Wu H, MacLeod AR, Lima WF, Crooke ST: Identification and partial purification of human double strand RNase activity. A novel terminating mechanism for oligoribonucleotide antisense drugs. J Biol Chem (1998) 273:2532-2542.
67. Donis-Keller H: Site-specific enzymatic cleavage of RNA. Nucleic Acids Res (1979) 7:179-192.
68. Woolf TM, Melton DA, Jennings CGB: Specificity of antisense oligonucleotides in vivo. Proc Natl Acad Sci USA (1992) 89:7305-7309.
69. Seidman S, Eckstein F, Grifman M, Soreq H: Antisense technologies have a future fighting neurodegenerative diseases. Antisense Nucleic Acid Drug Dev (1999) 9:333-340.
70. Corey DR: Peptide nucleic acids: Expanding the scope of nucleic acid recognition. Trends Biotechnol (1997) 15:224-229.
71. Summerton J, Weller D: Morpholino antisense oligomers: Design, preparation and properties. Antisense Nucleic Acid Drug Dev (1997) 7:187-195.
72. Stein D, Foster E, Huang S-B, Weller D, Summerton J: A specificity comparison of four antisense types: Morpholino, 2′-O-methyl RNA, DNA and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev (1997) 7:151-157.